Incyte (INCY) Return on Capital Employed (2011 - 2026)
Incyte's (INCY) quarterly Return on Capital Employed came in at 28.26% in Q2 2026, up 200.0% YoY from 9.42% in Q2 2025, and down 0.73% on a QoQ basis from 28.47% in Q1 2026.
Incyte (INCY) Return on Capital Employed (2011 - 2026) Analysis & Trends
Incyte (INCY) has 16 years of Return on Capital Employed data on file, last reported at 28.26% in Q2 2026.
- Quarterly Return on Capital Employed rose 200.0% year-over-year to 28.26% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 28.26% (up 200.0% YoY) and the FY2025 annual result came in at 32.33%, up 3096.0% from the prior year.
- Return on Capital Employed eased to 28.26% in Q2 2026, from 28.47% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 31.25% in Q3 2025 to a low of 1.59% in Q3 2024.
- A 5-year average of 14.43% and a median of 12.59% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 1131 bps — and 2025, when it jumped 3284 bps.
- Tracing INCY's Return on Capital Employed over 5 years: stood at 12.82% in 2022, then dropped by 9 bps to 11.61% in 2023, then tumbled by 85 bps to 1.71% in 2024, then jumped by 1626 bps to 29.54% in 2025, then decreased by 4 bps to 28.26% in 2026.
- The last three Return on Capital Employed figures came in at 28.26% (Q2 2026), 28.47% (Q1 2026), and 29.54% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 28.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.26% |
| Mar 31, 2026 | 28.47% |
| Dec 31, 2025 | 29.54% |
| Sep 30, 2025 | 31.25% |
| Jun 30, 2025 | 26.25% |
| Mar 31, 2025 | 4.50% |
| Dec 31, 2024 | 1.71% |
| Sep 30, 2024 | -1.59% |
| Jun 30, 2024 | 0.35% |
| Mar 31, 2024 | 12.36% |
| Dec 31, 2023 | 11.61% |
| Sep 30, 2023 | 9.73% |
| Jun 30, 2023 | 8.74% |
| Mar 31, 2023 | 10.13% |
| Dec 31, 2022 | 12.82% |
| Sep 30, 2022 | 14.07% |
| Jun 30, 2022 | 16.83% |
| Mar 31, 2022 | 14.69% |
| Dec 31, 2021 | 15.78% |
| Sep 30, 2021 | 19.32% |